Awards & Advancement

tranSMART platform named award finalist

Monday, August 31, 2015

The tranSMART Foundation, a nonprofit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, has announced its tranSMART v1.2 platform has been selected as a 2015 R&D 100 Award Finalist by R&D Magazine in the Software/Services category. The R&D 100 Award recognizes the 100 most technologically significant products introduced in the past year.

[Read More]

Halozyme taps Labarre as chief scientific officer

Monday, August 31, 2015

Halozyme Therapeutics, a San Diego-based biotechnology company developing novel oncology and drug-delivery therapies, has named Michael J. LaBarre, Ph.D., as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. The move broadens LaBarre’s responsibilities to include R&D of early pipeline assets, in addition to his role managing product development and ENHANZE platform partnerships.

[Read More]

Certara’s Mouksassi hired at UMontreal

Monday, August 31, 2015

Certara, a global biosimulation technology-enabled drug development company, has announced that director of pharmacometrics Samer Mouksassi, PharmD, Ph.D., FCP, has been appointed an associate professor in the faculty of pharmacy at the University of Montreal. Mouksassi will teach clinicians and students how biosimulation can be used to improve drug development and enhance health outcomes.

[Read More]

Brown, Zoda promoted at INC Research

Thursday, August 27, 2015

Raleigh, N.C.-based INC Research, a global phase I to IV CRO, has announced the promotions of Bekki Brown to executive vice president, clinical development and general medicine, and Tom Zoda, Ph.D., to executive vice president, clinical development, central nervous system (CNS).

[Read More]

Biocept CFO resigns; interim replacement named

Monday, August 24, 2015

Biocept, a San Diego-based molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, has announced the voluntary resignation of Bill Kachioff, senior vice president and chief financial officer, to pursue other business opportunities. The company also announced that Mark G. Foletta has been appointed as the company’s interim chief financial officer, effective immediately.

[Read More]